Trial · NCT02917863
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effects on gut inflammation parameter (Calprotectin) | 0-6-12 months | Calculate the difference in gut inflammation parameter (calprotectin) among the two groups of patients at T6-T0 and T12-T6 |
| Primary | Effects on gut absorption parameters | 0-6-12 months | Calculate the difference in gut absorption parameters (Steatocrit) among the two groups of patients at T6-T0 and T12-T6 |
| Primary | Effects on gut inflammation parameter (Osteoprotegerin) | 0-6-12 months | Calculate the difference in gut inflammation parameter (osteoprotegerin) among the two groups of patients at T6-T0 and T12-T6 |
| Primary | Effects on gut inflammation parameter (S100-A12 protein) | 0-6-12 months | Calculate the difference in gut inflammation parameter (S100-A12 protein) among the two groups of patients at T6-T0 and T12-T6 |
| Secondary | Baseline gut microbiota characterization | baseline | Qualitative and quantitative (percentage) characterization of gut microbiota before the start of the therapy (T0) |
| Secondary | Difference in gut microbiota among hypothyroid and healthy subjects | baseline | Difference in gut microbiota among hypothyroid patients (T0) and healthy patients (data from Human Microbiome Project) |
| Secondary | Incidence of deamidated AGA | 6-12-24 months | Estimate the incidence of positive patients to deamidated AGA at T6, T12, T24 (follow-up) |
| Secondary | Baseline gut inflammation parameters | baseline | Evaluate gut inflammation (calprotectin, Osteoprotegerin and S100-A12 protein) parameters before the start of the therapy (T0) |
| Secondary | Baseline gut absorption parameters | baseline | Evaluate gut absorption (Steatocrit) parameters before the start of the therapy (T0) |
| Secondary | Difference in Shannon Index in the gut microbiota among liquid and solid L-Thyroxine formulations | 0-6-12 moths | Calculate the difference in Shannon Index (index of diversity) among the two groups of patients at T6-T0 and T12-T6 |
| Secondary | Difference in Chao I in gut microbiota among liquid and solid L-Thyroxine formulations | 0-6-12 moths | Calculate the difference in Chao I (Species richness estimator) among the two groups of patients at T6-T0 and T12-T6 |
| Secondary | Difference in percentage of different species in gut microbiota among liquid and solid L-Thyroxine formulations | 0-6-12 moths | Calculate the difference in percentage of different species (OTU, operational taxonomic unit) among the two groups of patients at T6-T0 and T12-T6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02917863/registered